Fremanezumab
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Fremanezumab: Atrophoderma vermiculata
One-Sentence Summary
Fremanezumab is a humanised monoclonal antibody that targets calcitonin gene-related peptide (CGRP), originally used to prevent migraine. The TxGNN model predicts it may be effective for atrophoderma vermiculata, but there are currently no registered clinical trials and the 19 publications compiled are mostly observational studies, reviews and preclinical work on migraine or migraine aura in general, not this disease specifically.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Atrophoderma vermiculata |
| TxGNN Prediction Score | 0.9904 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, fremanezumab is a humanised monoclonal antibody that binds the CGRP ligand. CGRP signalling is central to trigeminovascular activation in migraine, and its efficacy in migraine prevention has been established.
The high TxGNN score (0.9904) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
There are also reasons for caution. A preclinical study (PMID 31127003) found that cortical spreading depression (the phenomenon thought to underlie aura)-induced arterial dilatation and plasma protein extravasation were unaffected by fremanezumab. A pilot cohort study (PMID 38091211) also highlights that the effectiveness of anti-CGRP antibodies on aura remains uncertain.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Of the 19 publications compiled, the most relevant to aura and the predicted indication are listed below (up to 10; study types are as classified in the compiled data).
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41618146 | 2026 | Systematic review | J Headache Pain | Individual-patient quantitative synthesis of anti-CGRP antibodies in hemiplegic migraine, a rare aura subtype excluded from RCTs |
| 35302681 | 2022 | Post hoc cohort analysis | Eur J Neurol | Fremanezumab efficacy and quality-of-life outcomes in difficult-to-treat migraine, in subgroups with and without aura or similar neurological dysfunction (FOCUS study) |
| 38091211 | 2024 | Pilot prospective cohort | Neurol Sci | Pilot study of whether anti-CGRP antibodies are effective in preventing migraine with aura |
| 38332541 | 2024 | Observational case series | CNS Neurosci Ther | Effect of anti-CGRP therapy on migraine aura; prior clinical evidence described as limited |
| 31127003 | 2019 | Preclinical | J Neurosci | Fremanezumab did not affect cortical spreading depression-induced arterial dilatation or plasma protein extravasation, raising questions about CGRP’s role in aura |
| 28642283 | 2017 | Preclinical | J Neurosci | Selective inhibition of trigeminovascular neurons by fremanezumab |
| 37638190 | 2023 | Cohort | Front Neurol | Real-world 3-month efficacy and tolerability of fremanezumab in chronic migraine |
| 35775208 | 2022 | Observational | Cephalalgia | Effects of erenumab, fremanezumab and galcanezumab on prodromal and accompanying symptoms of migraine |
| 30725283 | 2019 | Review | Handb Exp Pharmacol | Overview of the role of CGRP in migraine |
| 42390441 | 2026 | Cohort | Cephalalgia | Cerebrovascular risk (ischaemic stroke or TIA) with CGRP antibodies versus onabotulinumtoxinA in migraine |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 12603H | Ajovy | Solution for injection 225 mg in 1.5 mL single-dose pre-filled syringe | Not available in the data compiled |
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for safety information.
Published real-world data raise some questions that warrant monitoring in any new use: a cohort study examined cerebrovascular risk (ischaemic stroke or TIA) with CGRP antibodies (PMID 42390441), and another examined glaucoma risk (PMID 42090640). These are observational and do not establish causation.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is biologically plausible because migraine with brainstem aura is a migraine subtype, but no clinical trials exist for it. The available literature is observational, preclinical or general to migraine, and some of it questions whether CGRP blockade affects aura mechanisms. At this stage it is best treated as a research question rather than a candidate for clinical adoption. The other nine predictions in the data (for example atrophoderma vermiculata, thrombophilia and sciatic neuropathy) have no trials or literature and no plausible mechanistic link, so they are not recommended for further evaluation.
To proceed, the following is needed:
- Mechanism of action data (e.g. from DrugBank)
- The TGA-approved Product Information, including warnings, contraindications and the approved indication text
- Prospective studies or pooled analyses of fremanezumab specifically in migraine with brainstem aura (and related rare aura subtypes such as hemiplegic migraine)
- Review of cerebrovascular safety data, given the questions raised in observational studies, before any use in patients with aura-related neurological symptoms
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.